Details of the Drug Combination

General Information of Drug Combination (ID: DCDBEHC)

• Drug Combination Name: Amonafide + DFN-15
• Indication: Lung adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Amonafide (DMAH59S): Small molecular drug
  DFN-15 (DM3BF9B): N.A.
• High-throughput Screening Result:
  Testing Cell Line: HOP-62
  Zero Interaction Potency (ZIP) Score: 4.81
  Bliss Independence Score: 6.64
  Loewe Additivity Score: 4.41
  LHighest Single Agent (HSA) Score: 6.49

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCGRDY0	A549	Investigative	[1]
Adenocarcinoma	DCY01FH	HCT116	Investigative	[1]
Chronic myelogenous leukemia	DCJ0YEY	K-562	Investigative	[1]
Clear cell renal cell carcinoma	DC4UVDX	786-0	Investigative	[1]
Renal cell carcinoma	DCBQ1AC	SN12C	Investigative	[1]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)